Chronic obstructive pulmonary disease: An update of treatment related to frequently associated comorbidities

Therapeutic Advances in Chronic Disease

Volumn 1, Issue 2, 2010, Pages 43-57

  Sinden, Nicola J ^a   Stockley, Robert A ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

angiotensin converting enzyme inhibitors; anti inflammatory drugs; chronic obstructive pulmonary disease; comorbidity; peroxisome proliferator activated receptor agonists; statins; systemic inflammation

Indexed keywords

ANTIINFLAMMATORY AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CIGLITAZONE; CILOMILAST; CORTICOSTEROID; DILMAPIMOD; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; I KAPPA B; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; PRAVASTATIN; ROFLUMILAST; ROLIPRAM; ROSIGLITAZONE; SALMETEROL; TIOTROPIUM BROMIDE; TUMOR NECROSIS FACTOR INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DIABETES MELLITUS; DIARRHEA; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG WITHDRAWAL; DYSLIPIDEMIA; HEADACHE; HUMAN; INFLAMMATION; INHALATION; LUNG CANCER; MORTALITY; MYOPATHY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOPOROSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SIDE EFFECT; SMOKING CESSATION; WEIGHT REDUCTION;

EID: 79952924636     PISSN: 20406223     EISSN: None     Source Type: Journal    
DOI: 10.1177/2040622310370631     Document Type: Review

References (129)

1. Aalbers, R., Ayres, J., Backer, V., Decramer, M., Lier, P.A., Magyar, P. et al. (2002) Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Eur Respir J 19: 936-943.
2. Adcock, I.M., Chung, K.F., Caramori, G. and Ito, K. ( 2006) Kinase inhibitors and airway inflammation. Eur J Pharmacol 533: 118-132.
3. Agusti, A., Morla, M., Sauleda, J., Saus, C. and Busquets, X. ( 2004) NF-kappaB activation and iNOS upregulation in skeletal muscle of patients with COPD and low body weight. Thorax 59: 483-487.
4. Agusti, A.G., Noguera, A., Sauleda, J., Sala, E., Pons, J. and Busquets, X. ( 2003) Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 21: 347-360.
5. Alexeeff, S.E., Litonjua, A.A., Sparrow, D., Vokonas, P.S. and Schwartz, J. ( 2007) Statin use reduces decline in lung function: VA Normative Aging Study. Am J Respir Crit Care Med 176: 742-747.
6. Anthonisen, N.R., Skeans, M.A., Wise, R.A., Manfreda, J., Kanner, R.E. and Connett, J.E. ( 2005) The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 142: 233-239.
7. Araujo, E.P., de Souza, C.T., Ueno, M., Cintra, D.E., Bertolo, M.B., Carvalheira, J.B. et al. (2007) Infliximab restores glucose homeostasis in an animal model of diet-induced obesity and diabetes. Endocrinology 148: 5991-5997.
8. Arora, O.P., Kapoor, C.P. and Sobti, P. ( 1968) Study of gastroduodenal abnormalities in chronic bronchitis and emphysema. Am J Gastroenterol 50: 289-296.
9. Barczyk, A., Pierzchala, W., Kon, O.M., Cosio, B., Adcock, I.M. and Barnes, P.J. ( 2006) Cytokine production by bronchoalveolar lavage T lymphocytes in chronic obstructive pulmonary disease. J Allergy Clin Immunol 117: 1484-1492.
10. Barnes, P.J. ( 2007) Unexpected failure of anti-tumor necrosis factor therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175: 866-867.
11. Barnes, P.J. and Celli, B.R. (2009) Systemic manifestations and comorbidities of COPD. Eur Respir J 33: 1165-1185.
12. Belvisi, M.G. and Hele, D.J. ( 2008) Peroxisome proliferator-activated receptors as novel targets in lung disease. Chest 134: 152-157.
13. Belvisi, M.G. and Mitchell, J.A. (2009) Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease. Br J Pharmacol 158: 994-1003.
14. Berger, J.P., Akiyama, T.E. and Meinke, P.T. ( 2005) PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci 26: 244-251.
15. Birrell, M.A., Patel, H.J., McCluskie, K., Wong, S., Leonard, T., Yacoub, M.H. et al. (2004) PPAR-gamma agonists as therapy for diseases involving airway neutrophilia. Eur Respir J 24: 18-23.
16. Blamoun, A.I., Batty, G.N., de Bari, V.A., Rashid, A.O., Sheikh, M. and Khan, M.A. ( 2008) Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int J Clin Pract 62: 1373-1378.
17. Bolton, C.E., Ionescu, A.A., Shiels, K.M., Pettit, R.J., Edwards, P.H., Stone, M.D. et al. (2004) Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 170: 1286-1293.
18. Briggs, A.H., Lozano-Ortega, G., Spencer, S., Bale, G., Spencer, M.D. and Burge, P.S. ( 2006) Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value Health 9: 227-235.
19. Broekhuizen, R., Grimble, R.F., Howell, W.M., Shale, D.J., Creutzberg, E.C., Wouters, E.F. et al. (2005) Pulmonary cachexia, systemic inflammatory profile, and the interleukin 1beta -511 single nucleotide polymorphism. Am J Clin Nutr 82: 1059-1064.
20. Brugts, J.J., Yetgin, T., Hoeks, S.E., Gotto, A.M., Shepherd, J., Westendorp, R.G. et al. (2009) The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. Bmj 338: b2376.
21. Burge, P.S., Calverley, P.M., Jones, P.W., Spencer, S., Anderson, J.A. and Maslen, T.K. ( 2000) Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Bmj 320: 1297-1303.
22. Busquets, X., MacFarlane, N.G., Heine-Suner, D., Morla, M., Torres-Juan, L., Iglesias, A. et al. (2007) Angiotensin-converting-enzyme gene polymorphisms, smoking and chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2: 329-334.
23. Calverley, P.M., Anderson, J.A., Celli, B., Ferguson, G.T., Jenkins, C., Jones, P.W. et al. (2007) Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356: 775-789.
24. Calverley, P.M., Rabe, K.F., Goehring, U.M., Kristiansen, S., Fabbri, L.M. and Martinez, F.J. (2009) Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 374: 685-694.
25. Caramori, G., Romagnoli, M., Casolari, P., Bellettato, C., Casoni, G., Boschetto, P. et al. (2003) Nuclear localisation of p 65 in sputum macrophages but not in sputum neutrophils during COPD exacerbations. Thorax 58: 348-351.
26. Casaburi, R., Mahler, D.A., Jones, P.W., Wanner, A., San, P.G., ZuWallack, R.L. et al. (2002) A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 19: 217-224.
27. Celli, B., Decramer, M., Kesten, S., Liu, D., Mehra, S. and Tashkin, D.P. (2009) Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 180: 948-955.
28. Celli, B.R., Thomas, N.E., Anderson, J.A., Ferguson, G.T., Jenkins, C.R., Jones, P.W. et al. (2008) Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 178: 332-338.
29. Cenci, S., Weitzmann, M.N., Roggia, C., Namba, N., Novack, D., Woodring, J. et al. (2000) Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest 106: 1229-1237.
30. Chandler, M.A. and Rennard, S.I. (2010) Smoking cessation. Chest 137: 428-435.
31. Churg, A., Wang, R.D., Tai, H., Wang, X., Xie, C. and Wright, J.L. ( 2004) Tumor necrosis factor-alpha drives 70% of cigarette smoke-induced emphysema in the mouse. Am J Respir Crit Care Med 170: 492-498.
32. Compton, C.H., Gubb, J., Nieman, R., Edelson, J., Amit, O., Bakst, A. et al. (2001) Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet 358: 265-270.
33. Cote, C., Zilberberg, M.D., Mody, S.H., Dordelly, L.J. and Celli, B. ( 2007) Haemoglobin level and its clinical impact in a cohort of patients with COPD. Eur Respir J 29: 923-929.
34. Dahl, R., Greefhorst, L.A., Nowak, D., Nonikov, V., Byrne, A.M., Thomson, M.H. et al. (2001) Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164: 778-784.
35. de Boer, W.I., Yao, H. and Rahman, I. ( 2007) Future therapeutic treatment of COPD: struggle between oxidants and cytokines. Int J Chron Obstruct Pulmon Dis 2: 205-228.
36. de Godoy, I., Donahoe, M., Calhoun, W.J., Mancino, J. and Rogers, R.M. ( 1996) Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients. Am J Respir Crit Care Med 153: 633-637.
37. de Torres, J.P., Pinto-Plata, V., Casanova, C., Mullerova, H., Cordoba-Lanus, E., Muros de Fuentes, M. et al. (2008) C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest 133: 1336-1343.
38. Delayre-Orthez, C., Becker, J., Guenon, I., Lagente, V., Auwerx, J., Frossard, N. et al. (2005) PPARalpha downregulates airway inflammation induced by lipopolysaccharide in the mouse. Respir Res 6: 91.
39. Di Francia, M., Barbier, D., Mege, J.L. and Orehek, J. ( 1994) Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 150: 1453-1455.
40. Di Stefano, A., Caramori, G., Oates, T., Capelli, A., Lusuardi, M., Gnemmi, I. et al. (2002) Increased expression of nuclear factor-kappaB in bronchial biopsies from smokers and patients with COPD. Eur Respir J 20: 556-563.
41. Edwards, M.R., Bartlett, N.W., Clarke, D., Birrell, M., Belvisi, M. and Johnston, S.L. (2009) Targeting the NF-kappaB pathway in asthma and chronic obstructive pulmonary disease. Pharmacol Ther 121: 1-13.
42. Fabbri, L.M., Calverley, P.M., Izquierdo-Alonso, J.L., Bundschuh, D.S., Brose, M., Martinez, F.J. et al. (2009) Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 374: 695-703.
43. Finkelstein, J., Cha, E. and Scharf, S.M. (2009) Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. Int J Chron Obstruct Pulmon Dis 4: 337-349.
44. Gamble, E., Grootendorst, D.C., Brightling, C.E., Troy, S., Qiu, Y., Zhu, J. et al. (2003) Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 168: 976-982.
45. Gan, W.Q., Man, S.F., Senthilselvan, A. and Sin, D.D. ( 2004) Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 59: 574-580.
46. Genovese, T., Cuzzocrea, S., Di Paola, R., Mazzon, E., Mastruzzo, C., Catalano, P. et al. (2005) Effect of rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J 2 on bleomycin-induced lung injury. Eur Respir J 25: 225-234.
47. Gianni, W., Ricci, A., Gazzaniga, P., Brama, M., Pietropaolo, M., Votano, S. et al. (2004) Raloxifene modulates interleukin-6 and tumor necrosis factor-alpha synthesis in vivo: results from a pilot clinical study. J Clin Endocrinol Metab 89: 6097-6099.
48. Grootendorst, D.C., Gauw, S.A., Verhoosel, R.M., Sterk, P.J., Hospers, J.J., Bredenbroker, D. et al. (2007) Reduction in sputum neutrophil and eosinophil numbers by the PDE 4 inhibitor roflumilast in patients with COPD. Thorax 62: 1081-1087.
49. Halvorsen, B., Lund Sagen, E., Ueland, T., Aukrust, P. and Tonstad, S. ( 2007) Effect of smoking cessation on markers of inflammation and endothelial cell activation among individuals with high risk for cardiovascular disease. Scand J Clin Lab Invest 67: 604-611.
50. Ichinose, M. ( 2009) Differences of inflammatory mechanisms in asthma and COPD. Allergol Int 58: 307-313.
51. Johnson, B.A., Iacono, A.T., Zeevi, A., McCurry, K.R. and Duncan, S.R. ( 2003) Statin use is associated with improved function and survival of lung allografts. Am J Respir Crit Care Med 167: 1271-1278.
52. Karin, M., Yamamoto, Y. and Wang, Q.M. ( 2004) The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 3: 17-26.
53. Katsura, H. and Kida, K. ( 2002) A comparison of bone mineral density in elderly female patients with COPD and bronchial asthma. Chest 122: 1949-1955.
54. Kellow, J.E., Tao, Z. and Piper, D.W. ( 1986) Ventilatory function in chronic peptic ulcer. A controlled study of ventilatory function in patients with gastric and duodenal ulcer. Gastroenterology 91: 590-595.
55. Khurana, V., Bejjanki, H.R., Caldito, G. and Owens, M.W. ( 2007) Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans. Chest 131: 1282-1288.
56. Kim, H.C., Mofarrahi, M. and Hussain, S.N. ( 2008) Skeletal muscle dysfunction in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 3: 637-658.
57. Kony, S., Zureik, M., Driss, F., Neukirch, C., Leynaert, B. and Neukirch, F. ( 2004) Association of bronchial hyperresponsiveness and lung function with C-reactive protein (CRP): a population based study. Thorax 59: 892-896.
58. Kota, B.P., Huang, T.H. and Roufogalis, B.D. ( 2005) An overview on biological mechanisms of PPARs. Pharmacol Res 51: 85-94.
59. Kunik, M.E., Roundy, K., Veazey, C., Souchek, J., Richardson, P., Wray, N.P. et al. (2005) Surprisingly high prevalence of anxiety and depression in chronic breathing disorders. Chest 127: 1205-1211.
60. Lagrand, W.K., Visser, C.A., Hermens, W.T., Niessen, H.W., Verheugt, F.W., Wolbink, G.J. et al. (1999) C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation 100: 96-102.
61. Lee, J.C., Kumar, S., Griswold, D.E., Underwood, D.C., Votta, B.J. and Adams, J.L. ( 2000) Inhibition of p 38 MAP kinase as a therapeutic strategy. Immunopharmacology 47: 185-201.
62. Lee, J.H., Lee, D.S., Kim, E.K., Choe, K.H., Oh, Y.M., Shim, T.S. et al. (2005) Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med 172: 987-993.
63. Lee, T.M., Lin, M.S. and Chang, N.C. ( 2008) Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Am J Cardiol 101: 530-535.
64. Lekamwasam, S., Trivedi, D.P. and Khaw, K.T. ( 2005) An association between respiratory function and hip bone mineral density in older men: a cross-sectional study. Osteoporos Int 16: 204-207.
65. Lincoff, A.M., Wolski, K., Nicholls, S.J. and Nissen, S.E. ( 2007) Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. Jama 298: 1180-1188.
66. Lotvall, J. ( 2001) Pharmacological similarities and differences between beta2-agonists. Respir Med 95(Suppl B): S7-S11.
67. Man, S.F., Connett, J.E., Anthonisen, N.R., Wise, R.A., Tashkin, D.P. and Sin, D.D. ( 2006) C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 61: 849-853.
68. Mancini, G.B., Etminan, M., Zhang, B., Levesque, L.E., FitzGerald, J.M. and Brophy, J.M. ( 2006) Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 47: 2554-2560.
69. Mannino, D.M., Thorn, D., Swensen, A. and Holguin, F. ( 2008) Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 32: 962-969.
70. Martorana, P.A., Beume, R., Lucattelli, M., Wollin, L. and Lungarella, G. ( 2005) Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am J Respir Crit Care Med 172: 848-853.
71. Matera, M.G., Calzetta, L. and Cazzola, M. (2010) TNF-alpha inhibitors in asthma and COPD: we must not throw the baby out with the bath water. Pulm Pharmacol Ther 23: 121-128.
72. McAllister, D.A., Maclay, J.D., Mills, N.L., Mair, G., Miller, J., Anderson, D. et al. (2007) Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 176: 1208-1214.
73. Medicherla, S., Fitzgerald, M.F., Spicer, D., Woodman, P., Ma, J.Y., Kapoun, A.M. et al. (2008) p38alpha-selective mitogen-activated protein kinase inhibitor SD-282 reduces inflammation in a subchronic model of tobacco smoke-induced airway inflammation. J Pharmacol Exp Ther 324: 921-929.
74. Melbye, H., Halvorsen, D.S., Hartz, I., Medbo, A., Brox, J., Eggen, A.E. et al. (2007) Bronchial airflow limitation, smoking, body mass index, and statin use are strongly associated with the C-reactive protein level in the elderly. The Tromso Study 2001. Respir Med 101: 2541-2549.
75. Mills, N.L., Miller, J.J., Anand, A., Robinson, S.D., Frazer, G.A., Anderson, D. et al. (2008) Increased arterial stiffness in patients with chronic obstructive pulmonary disease: a mechanism for increased cardiovascular risk. Thorax 63: 306-311.
76. Mortensen, E.M., Copeland, L.A., Pugh, M.J., Restrepo, M.I., de Molina, R.M., Nakashima, B. et al. (2009) Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res 10: 45.
77. Moss, S.E., Klein, R. and Klein, B.E. ( 1991) Cause-specific mortality in a population-based study of diabetes. Am J Public Health 81: 1158-1162.
78. Mueller, C., Weaver, V., Vanden Heuvel, J.P., August, A. and Cantorna, M.T. ( 2003) Peroxisome proliferator-activated receptor gamma ligands attenuate immunological symptoms of experimental allergic asthma. Arch Biochem Biophys 418: 186-196.
79. Mukhopadhyay, T., Roth, J.A. and Maxwell, S.A. ( 1995) Altered expression of the p 50 subunit of the NF-kappa B transcription factor complex in non-small cell lung carcinoma. Oncogene 11: 999-1003.
80. Norwood, R.J. ( 2007) A review of etiologies of depression in COPD. Int J Chron Obstruct Pulmon Dis 2: 485-491.
81. Paraskevas, K.I., Tzovaras, A.A., Briana, D.D. and Mikhailidis, D.P. ( 2007) Emerging indications for statins: a pluripotent family of agents with several potential applications. Curr Pharm Des 13: 3622-3636.
82. Pauwels, R.A., Buist, A.S., Calverley, P.M., Jenkins, C.R. and Hurd, S.S. ( 2001) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 163: 1256-1276.
83. Pickup, J.C., Mattock, M.B., Chusney, G.D. and Burt, D. ( 1997) NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40: 1286-1292.
84. Rana, J.S., Mittleman, M.A., Sheikh, J., Hu, F.B., Manson, J.E., Colditz, G.A. et al. (2004) Chronic obstructive pulmonary disease, asthma, and risk of type 2 diabetes in women. Diabetes Care 27: 2478-2484.
85. Rascon-Aguilar, I.E., Pamer, M., Wludyka, P., Cury, J., Coultas, D., Lambiase, L.R. et al. (2006) Role of gastroesophageal reflux symptoms in exacerbations of COPD. Chest 130: 1096-1101.
86. Reid, M.B. and Li, Y.P. ( 2001) Tumor necrosis factor-alpha and muscle wasting: a cellular perspective. Respir Res 2: 269-272.
87. Remels, A.H., Gosker, H.R., Schrauwen, P., Langen, R.C. and Schols, A.M. ( 2008) Peroxisome proliferator-activated receptors: a therapeutic target in COPD? Eur Respir J 31: 502-508.
88. Remels, A.H., Schrauwen, P., Broekhuizen, R., Willems, J., Kersten, S., Gosker, H.R. et al. (2007) Peroxisome proliferator-activated receptor expression is reduced in skeletal muscle in COPD. Eur Respir J 30: 245-252.
89. Rennard, S.I., Anderson, W., ZuWallack, R., Broughton, J., Bailey, W., Friedman, M. et al. (2001) Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 163: 1087-1092.
90. Ridker, P.M., Rifai, N., Rose, L., Buring, J.E. and Cook, N.R. ( 2002) Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347: 1557-1565.
91. Roussos, A., Philippou, N., Krietsepi, V., Anastasakou, E., Alepopoulou, D., Koursarakos, P. et al. (2005) Helicobacter pylori seroprevalence in patients with chronic obstructive pulmonary disease. Respir Med 99: 279-284.
92. Sabit, R., Bolton, C.E., Edwards, P.H., Pettit, R.J., Evans, W.D., McEniery, C.M. et al. (2007) Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175: 1259-1265.
93. Scanlon, P.D., Connett, J.E., Waller, L.A., Altose, M.D., Bailey, W.C. and Buist, A.S. ( 2000) Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 161: 381-390.
94. Schols, A.M., Buurman, W.A., Staal van den Brekel, A.J., Dentener, M.A. and Wouters, E.F. ( 1996) Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax 51: 819-824.
95. Sevenoaks, M.J. and Stockley, R.A. ( 2006) Chronic Obstructive Pulmonary Disease, inflammation and co-morbidity-a common inflammatory phenotype? Respir Res 7: 70.
96. Simon, D.M., Arikan, M.C., Srisuma, S., Bhattacharya, S., Tsai, L.W., Ingenito, E.P. et al. (2006) Epithelial cell PPAR[gamma] contributes to normal lung maturation. Faseb J 20: 1507-1509.
97. Sin, D.D., Anthonisen, N.R., Soriano, J.B. and Agusti, A.G. ( 2006) Mortality in COPD: Role of comorbidities. Eur Respir J 28: 1245-1257.
98. Sin, D.D., Lacy, P., York, E. and Man, S.F. ( 2004) Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 170: 760-765.
99. Sin, D.D. and Man, S.F. ( 2005a) Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2: 8-11.
100. Sin, D.D. and Man, S.F. ( 2005b) Chronic obstructive pulmonary disease: a novel risk factor for cardiovascular disease. Can J Physiol Pharmacol 83: 8-13.
101. Sin, D.D., Wu, L. and Man, S.F. ( 2005) The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest 127: 1952-1959.
102. Sinden, N.J. and Stockley, R.A. ( 2010) Systemic inflammation and comorbidity in COPD: A result of “overspill” of inflammatory mediators from the lungs? A review of the evidence. Thorax, in press.
103. Singh, D., Smyth, L., Borrill, Z., Sweeney, L. and Tal-Singer, R. (2010) A randomized, placebo-controlled study of the effects of the p 38 MAPK inhibitor SB-681323 on blood biomarkers of inflammation in COPD patients. J Clin Pharmacol 50: 94-100.
104. Singh, S., Loke, Y.K. and Furberg, C.D. ( 2007) Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. Jama 298: 1189-1195.
105. Singh, S., Loke, Y.K. and Furberg, C.D. ( 2008) Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Jama 300: 1439-1450.
106. Smith Jr, S.C., Allen, J., Blair, S.N., Bonow, R.O., Brass, L.M., Fonarow, G.C. et al. (2006 a) AHA / ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113: 2363-2372.
107. Smith, S.J., Fenwick, P.S., Nicholson, A.G., Kirschenbaum, F., Finney-Hayward, T.K., Higgins, L.S. et al. (2006 b) Inhibitory effect of p 38 mitogen-activated protein kinase inhibitors on cytokine release from human macrophages. Br J Pharmacol 149: 393-404.
108. Sonnenberg, G.E., Krakower, G.R. and Kissebah, A.H. ( 2004) A novel pathway to the manifestations of metabolic syndrome. Obes Res 12: 180-186.
109. Sovani, M.P., Whale, C.I. and Tattersfield, A.E. ( 2004) A benefit-risk assessment of inhaled longacting beta2-agonists in the management of obstructive pulmonary disease. Drug Saf 27: 689-715.
110. Soyseth, V., Brekke, P.H., Smith, P. and Omland, T. ( 2007) Statin use is associated with reduced mortality in COPD. Eur Respir J 29: 279-283.
111. Stavem, K., Aaser, E., Sandvik, L., Bjornholt, J.V., Erikssen, G., Thaulow, E. et al. (2005) Lung function, smoking and mortality in a 26-year follow-up of healthy middle-aged males. Eur Respir J 25: 618-625.
112. Suissa, S., Ernst, P. and Hudson, M. ( 2008) TNF-alpha antagonists and the prevention of hospitalisation for chronic obstructive pulmonary disease. Pulm Pharmacol Ther 21: 234-238.
113. Sun, H., Koike, T., Ichikawa, T., Hatakeyama, K., Shiomi, M., Zhang, B. et al. (2005) C-reactive protein in atherosclerotic lesions: its origin and pathophysiological significance. Am J Pathol 167: 1139-1148.
114. Swallow, E.B., Reyes, D., Hopkinson, N.S., Man, W.D., Porcher, R., Cetti, E.J. et al. (2007) Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease. Thorax 62: 115-120.
115. Takabatake, N., Nakamura, H., Abe, S., Inoue, S., Hino, T., Saito, H. et al. (2000) The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 161: 1179-1184.
116. Tang, Q.O., Tran, G.T., Gamie, Z., Graham, S., Tsialogiannis, E., Tsiridis, E. et al. (2008) Statins: under investigation for increasing bone mineral density and augmenting fracture healing. Expert Opin Investig Drugs 17: 1435-1463.
117. Tashkin, D.P., Celli, B., Senn, S., Burkhart, D., Kesten, S., Menjoge, S. et al. (2008) A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359: 1543-1554.
118. Underwood, D.C., Osborn, R.R., Bochnowicz, S., Webb, E.F., Rieman, D.J., Lee, J.C. et al. (2000) SB 239063, a p 38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am J Physiol Lung Cell Mol Physiol 279: L895-L902.
119. van Gestel, Y.R., Hoeks, S.E., Sin, D.D., Huzeir, V., Stam, H., Mertens, F.W. et al. (2009) COPD and cancer mortality: the influence of statins. Thorax 64: 963-967.
120. van Gestel, Y.R., Hoeks, S.E., Sin, D.D., Simsek, C., Welten, G.M., Schouten, O. et al. (2008) Effect of statin therapy on mortality in patients with peripheral arterial disease and comparison of those with versus without associated chronic obstructive pulmonary disease. Am J Cardiol 102: 192-196.
121. Vestbo, J., Tan, L., Atkinson, G. and Ward, J. (2009) A controlled trial of 6-weeks’ treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD. Eur Respir J 33: 1039-1044.
122. Waddleton, D., Wu, W., Feng, Y., Thompson, C., Wu, M., Zhou, Y.P. et al. (2008) Phosphodiesterase 3 and 4 comprise the major cAMP metabolizing enzymes responsible for insulin secretion in INS-1 (832 / 13) cells and rat islets. Biochem Pharmacol 76: 884-893.
123. Wannamethee, S.G., Lowe, G.D., Shaper, A.G., Rumley, A., Lennon, L. and Whincup, P.H. ( 2005) Associations between cigarette smoking, pipe / cigar smoking, and smoking cessation, and haemostatic and inflammatory markers for cardiovascular disease. Eur Heart J 26: 1765-1773.
124. Wasswa-Kintu, S., Gan, W.Q., Man, S.F., Pare, P.D. and Sin, D.D. ( 2005) Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis. Thorax 60: 570-575.
125. Wedzicha, J.A., Calverley, P.M., Seemungal, T.A., Hagan, G., Ansari, Z. and Stockley, R.A. ( 2008) The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol / fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 177: 19-26.
126. Wouters, E.F., Reynaert, N.L., Dentener, M.A. and Vernooy, J.H. (2009) Systemic and local inflammation in asthma and chronic obstructive pulmonary disease: is there a connection? Proc Am Thorac Soc 6: 638-647.
127. Yang, P., Bamlet, W.R., Sun, Z., Ebbert, J.O., Aubry, M.C., Krowka, M.J. et al. (2005) Alpha1-antitrypsin and neutrophil elastase imbalance and lung cancer risk. Chest 128: 445-452.
128. Yao, W., Tian, X.Y., Chen, J., Setterberg, R.B., Lundy, M.W., Chmielzwski, P. et al. (2007) Rolipram, a phosphodiesterase 4 inhibitor, prevented cancellous and cortical bone loss by inhibiting endosteal bone resorption and maintaining the elevated periosteal bone formation in adult ovariectomized rats. J Musculoskelet Neuronal Interact 7: 119-130.
129. Young, R.P., Hopkins, R. and Eaton, T.E. (2009) Potential benefits of statins on morbidity and mortality in chronic obstructive pulmonary disease: a review of the evidence. Postgrad Med J 85: 414-421.